E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/28/2005 in the Prospect News Biotech Daily.

S&P rates Merck Finanz bond BBB+

Standard & Poor's said it assigned its BBB+ senior unsecured debt rating to the €500 million bond issued by Merck Finanz AG and guaranteed by parent Merck KGaA (BBB+/stable/A-2).

Proceeds will be used for unspecified corporate purposes and the refinancing of existing debt.

The rating on the bond is equalized with the long-term corporate credit rating on Merck, reflecting the existence of insufficient priority liabilities ranking ahead of the issue, the agency said.

The ratings on Merck are supported by its improving operational and financial performance as a result of the high market share of its growing chemicals business sector, the strongly improved outlook for its Liquid Crystals division and the positive early track record of its anticancer drug Erbitux, the agency said.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.